www.uams.edu/movementdisorders 

CLINICAL TRIALS       

IN PARKINSON'S DISEASE

Albuterol in Underweight, Fluctuating Patients with Parkinson's disease: A Pilot Study                                                        

• Recent weight loss AND 
• Decreased effectiveness of Carbidopa/Levodopa (SinemetÒ)
• Open label, at GCRC, funded by Biomedical Research Foundation

     Recruiting patients now!    $600  compensation             

• Phase III, multicenter, double-blind, randomized, placebo-controlled 
• At least 2.5 hours "off" (when medications are not effective) state per day
• No Selegiline (EldeprylÒ) within the last 90 days

• In connection with PSG (Parkinson Study Group)

• Phase IV, multicenter, double-blind, randomized, placebo-controlled
• No wearing-off or end-of-dose wearing off symptoms occurring no earlier than 4 hours after the most recent Carbidopa/Levodopa (SinemetÒ) dose
• No dyskinesia

    Recruiting patients now!

Contact Dr. Ergun Y. Uc by phone at 501-686-5135 or fax at 501-686-8689  or e-mail at ucerguny@exchange.uams.edu    or  write to Dept. of Neurology at UAMS, 4301  West Markham Slot 500, Little Rock AR 72205.